I.CERAM SA (FR:ALICR) has released an update.
I.Ceram SA reported a 46% decline in revenue for the first half of 2024, attributed to the loss of certification for key products, while operating losses grew despite cost-cutting measures. The company is focusing on advancing antibiotic-loaded ceramic implants and is in the process of judicial recovery, with a restructuring plan due in November. Listed on Euronext Growth, I.Ceram is leveraging its innovative bioceramic technologies to drive future growth.
For further insights into FR:ALICR stock, check out TipRanks’ Stock Analysis page.